Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Opus Genetics, Inc.NASDAQ: IRD
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$51.17M, compared with $1.74M a year earlier. Trailing-twelve-month other income / expenses was -$63.9M.
Context
- Other income / expenses amounted to 77.4% of revenue in FY2025, up 36.1 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$51.17M or moves back toward the trailing-twelve-month quarterly average of -$15.97M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (10.99M) USD
- Year-over-year change
- -342.0%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.99M) | -342.0% |
| FY2024 | 2024-12-31 | 4.54M | +671.1% |
| FY2023 | 2023-12-31 | 589K | +2660.9% |
| FY2022 | 2022-12-31 | (23K) | +99.9% |
| FY2021 | 2021-12-31 | (33.99M) | — |
Other Income / Expenses vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 other income / expenses of -$63.9M is the lowest of the 10 companies compared; the peer median is $6.66M.
- Its year-over-year change of -1226.0% is the lowest of 10, against a peer median of -24.4%.
- Other income / expenses amounts to 533.2% of revenue for IRD, versus a peer median of 52.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $54.3M | +157.6% | — | 43.8% | |
| LTM Mar 2026 | $40.74M | -24.4% | — | 3552.1% | |
| LTM Mar 2026 | $23.26M | +14.4% | +3.1% | — | |
| LTM Mar 2026 | $11.31M | -50.1% | -26.8% | 61.4% | |
| LTM Mar 2026 | $6.66M | +277.0% | — | — | |
| LTM Mar 2026 | $4.27M | -57.4% | -0.2% | 28.4% | |
| LTM Mar 2026 | $1.38M | +179.7% | +128.1% | — | |
| LTM Mar 2026 | $1.34M | -87.1% | +1.6% | — | |
| LTM Mar 2026 | -$1.21M | -112.8% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$63.9M | -1226.0% | — | 533.2% |
| Peer median (excluding IRD) | $6.66M | -24.4% | +1.6% | 52.6% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 589K | 39.85M | 19.05M | 10.99M | 14.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 15.17M | 14.36M | 17.65M | 26.85M | 30.81M |
| Selling, General & Admin | 8.12M | 7.27M | 11.96M | 18.22M | 21.98M |
| Operating Expenses | 23.29M | 21.62M | 29.61M | 73.07M | 52.8M |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| EBITDA | (56.69M) | 18.22M | (9.97M) | (57.52M) | (48.07M) |
| EBITDA Margin | -9624.3% | 45.7% | -52.3% | -523.3% | -338.6% |
| Operating Income | (22.71M) | 18.23M | (10.56M) | (62.07M) | (38.6M) |
| Operating Margin | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2K | 9K | 1.33M | 0 | 1.47M |
| Other Income / Expenses | (33.99M) | (23K) | 589K | 4.54M | (10.99M) |
| Income Before Tax | (56.69M) | 18.2M | (9.97M) | (57.53M) | (49.59M) |
| Pre-Tax Margin | -9625.3% | 45.7% | -52.4% | -523.4% | -349.3% |
| Income Tax Expense | 0 | 315K | 12K | 0 | 0 |
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Net Margin | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (Basic) | (3.82) | 0.90 | (0.46) | (2.15) | (0.80) |
| EPS (Diluted) | (3.82) | 0.87 | (0.46) | (2.15) | (0.80) |
| Weighted Avg Shares | 14.85M | 19.93M | 21.59M | 26.72M | 622.22M |
| Weighted Avg Shares (Diluted) | 14.85M | 20.6M | 21.59M | 26.72M | 622.22M |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.